Utilization data from the Central Transfusion Registry shows that IG use in BC has been increasing at approximately 10% per year.
Immunology comprises the largest speciality and accounts for 45% of Provincial IG use. The condition Primary Immunodeficiency or Primary Immune Deficiency Disease (PIDD) accounts for approximately 60% of IG used for immunology patients and the growth of utilization year over year has been significant. Highlights of our analysis demonstrate increasing annual dosage, prescriber variation and a steady increase in new and chronic patients, particularly in the sixth and seventh decade of life.
In 2016 the PIDD Working Group was formed in order to help establish a provincial framework for IG use in PIDD. The Working Group representatives include: Dr. Doug Morrison (co-chair), Dr. Karen Dallas (co-chair), Dr. Bob Schellenberg, Dr. Donald Stark, Dr. Hein Reeves, Dr. Peter Lee, Dr. Kingsley Lee , Dr. Seung Kim, and Dr. Kyla Hildebrand.
The Working Group participated in the development of the Diagnostic and Treatment Algorithms as well as the PIDD Toolkit App.
If you have questions or would like to learn more, please contact PBCO